Premium
Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia
Author(s) -
Endo Takeshi,
Yatomi Yutaka,
Amemiya Norihiko,
Mizoe Asako,
Iino Masaki,
Ozawa Hideyuki,
Hosogaya Shigemi,
Ozaki Yukio
Publication year - 2000
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(200003)63:3<145::aid-ajh7>3.0.co;2-e
Subject(s) - waldenstrom macroglobulinemia , macroglobulinemia , partial thromboplastin time , coagulation , medicine , antibody , rituximab , immunology , factor ix , lymphoplasmacytic lymphoma , thromboplastin , titer , immunoglobulin m , factor vii , gastroenterology , immunoglobulin g , lymphoma , multiple myeloma
We report a case of Waldenström's macroglobulinemia with prominent bleeding tendency; laboratory investigation revealed an elevated activated partial thromboplastin time. Further laboratory evaluation showed circulating factor VIII anticoagulant, deemed polyclonal IgG, with a titer of 700 Bethesda Units/ml. The factor VIII inactivation kinetics of the patient plasma were identical to those of a type II inhibitor, and the inhibitor was found to recognize the A2 domain of the factor VIII heavy chain. Apparently, paraprotein is not always the cause of reduced activity of coagulation factors in neoplastic dysproteinemias. Am. J. Hematol. 63: 145–148, 2000. © 2000 Wiley‐Liss, Inc.